Chi Qi1, Hao Zhang2, Yue Chen1, Song Su2, XiaoFeng Wang3, XinQiao Huang3, Cheng Fang2, Bo Li2, XianMing Xia4, Pan He5. 1. Department of Nuclear Medicine, Affiliated Hospital, Southwest Medical University, Luzhou, 646000, China; Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, 646000, China. 2. Department of Hepatobiliary Surgery, Affiliated Hospital, Southwest Medical University, Luzhou, 646000, China. 3. Department of Radiology, Affiliated Hospital, Southwest Medical University, Luzhou, 646000, China. 4. Department of Hepatobiliary Surgery, Affiliated Hospital, Southwest Medical University, Luzhou, 646000, China; Academician(Expert)Workstation of Sichuan Province, Luzhou, 646000, China. Electronic address: xxm6202@126.com. 5. Department of Hepatobiliary Surgery, Affiliated Hospital, Southwest Medical University, Luzhou, 646000, China; Academician(Expert)Workstation of Sichuan Province, Luzhou, 646000, China; Department of Anesthesiology, Affiliated Hospital, Southwest Medical University, Luzhou, 646000, China. Electronic address: 18783096517@163.com.
Abstract
BACKGROUND: This meta-analysis was conducted to evaluate the effectiveness and safety of indocyanine green fluorescence imaging-guided hepatectomy(FIGH) for liver tumors. METHODS: Clinical studies were retrieved from the PubMed, Embase, Cochrane Library, Medline and Web of Science electronic databases. Primary outcomes included operative time, blood loss, blood transfusion, hospital stay, R0 resection, postoperative complications, postoperative mortality and 1-year recurrence rate. Study-specific effect sizes and their 95% confidence intervals (CIs) were combined to calculate the pooled value using a fixed-effects or random-effects model. RESULTS: Six studies comprising 587 patients were included. Major operative time (mean difference [MD] = -55.45; 95% CI = -78.85- -32.05), blood loss (MD = 12.99; 95% CI = 12.00-13.97), hospital stay (rate difference [RD] = -12.61; 95% CI = -15.06- -10.17), and postoperative complications (RD = -0.07; 95% CI = -0.12- -0.01) were all less in the FIGH group than in the traditional hepatectomy(TH) group. No differences were found in blood transfusion, R0 resection or 1-year recurrence rate. No perioperative mortality was observed in either group. CONCLUSION: Based on current evidence, applying indocyanine green fluorescence imaging technology to accurately diagnose and treat liver tumors can effectively reduce operative time, blood loss, hospital stay and postoperative complications.
BACKGROUND: This meta-analysis was conducted to evaluate the effectiveness and safety of indocyanine green fluorescence imaging-guided hepatectomy(FIGH) for liver tumors. METHODS: Clinical studies were retrieved from the PubMed, Embase, Cochrane Library, Medline and Web of Science electronic databases. Primary outcomes included operative time, blood loss, blood transfusion, hospital stay, R0 resection, postoperative complications, postoperative mortality and 1-year recurrence rate. Study-specific effect sizes and their 95% confidence intervals (CIs) were combined to calculate the pooled value using a fixed-effects or random-effects model. RESULTS: Six studies comprising 587 patients were included. Major operative time (mean difference [MD] = -55.45; 95% CI = -78.85- -32.05), blood loss (MD = 12.99; 95% CI = 12.00-13.97), hospital stay (rate difference [RD] = -12.61; 95% CI = -15.06- -10.17), and postoperative complications (RD = -0.07; 95% CI = -0.12- -0.01) were all less in the FIGH group than in the traditional hepatectomy(TH) group. No differences were found in blood transfusion, R0 resection or 1-year recurrence rate. No perioperative mortality was observed in either group. CONCLUSION: Based on current evidence, applying indocyanine green fluorescence imaging technology to accurately diagnose and treat liver tumors can effectively reduce operative time, blood loss, hospital stay and postoperative complications.
Authors: Fernando Dip; Luigi Boni; Michael Bouvet; Thomas Carus; Michele Diana; Jorge Falco; Geoffrey C Gurtner; Takeaki Ishizawa; Norihiro Kokudo; Emanuele Lo Menzo; Philip S Low; Jaume Masia; Derek Muehrcke; Francis A Papay; Carlo Pulitano; Sylke Schneider-Koraith; Danny Sherwinter; Giuseppe Spinoglio; Laurents Stassen; Yasuteru Urano; Alexander Vahrmeijer; Eric Vibert; Jason Warram; Steven D Wexner; Kevin White; Raul J Rosenthal Journal: Ann Surg Date: 2022-04-01 Impact factor: 13.787
Authors: Wang Jianxi; Zou Xiongfeng; Zheng Zehao; Zhao Zhen; Peng Tianyi; Lin Ye; Jin Haosheng; Jian Zhixiang; Wang Huiling Journal: Front Oncol Date: 2022-07-19 Impact factor: 5.738